Bartolomé Vilanova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bartolomé Vilanova has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Josefa Donoso
Institut d’Investigació en Ciènces de la Salut (IUNICS), Departament de Química, Universitat de les Illes Balears, E-07122 Palma de Mallorca, Spain
37 shared publications - Miquel Adrover
Interdisciplinary Group on Neurodegeneration, Vascular and Metabolic Diseases (INNoVAM), Departament de Química, Universitat de les Illes Balears, Ctra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain
30 shared publications Francisco Muñoz
Institut Universitari d'Investigació en Ciències de la Salut (IUNICS). Departament de Química, Universitat de les Illes Balears, Ctra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain
25 shared publications- Juan Frau
Departament de Química, Facultat des Ciences, Universitat de les Illes Balears, Cra. Valldemossa Km. 7.5, Palma de Mallorca, E-07122, Spain
23 shared publications - Joaquín Ortega-Castro
Department de Quimica, University de les Illes Balears, Crta de Valldemossa km 7.5, 07122 Palma de Mallorca Baleares, Spain
12 shared publications - Laura Mariño
Université Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France
8 shared publications
Latest Publications
- Open Access
- 16 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (10) , 4799
On the Potential Role of Phytate Against Neurodegeneration: It Protects Against Fe3+-Catalyzed Degradation of Dopamine and Ascorbate and Against Fe3+-Induced Protein Aggregation
Myo-inositol-1,2,3,4,5,6-hexakisphosphate (IP6) is commonly found in plant-derived foods and has important pharmacological properties against many pathologies. One of them appears to be neurodegeneration, which is notably stimulated by dysregulated metal metabolism. Consequently, we explore the role of IP6 in mitigating neurodegenerative events catalyzed by dysregulated free iron. More precisely, we performed spectrophotometric measurements in aqueous solutions to investigate the ability of IP6 to chelate Fe3+ and inhibit its role in catalyzing the oxidative degradation of dopamine and ascorbic acid, two key molecules in neuronal redox systems. Our results demonstrate that IP6 effectively prevents the formation of harmful intermediates, such as neuromelanin and reactive oxygen species, which are linked to neuronal damage. Additionally, we assessed the effect of IP6 on Fe3+-induced protein aggregation, focusing on α-synuclein, which is closely associated with Parkinson’s disease. Our data reveal that IP6 accelerates the conversion of toxic α-synuclein oligomers into less harmful amyloid fibrils, thereby reducing their neurotoxic potential. Our findings highlight the dual function of IP6 as a potent Fe3+ chelator and modulator of protein aggregation pathways, reinforcing its potential as a neuroprotective agent. Consequently, IP6 offers promising therapeutic potential for mitigating the progression of neurodegenerative disorders such as Parkinson’s and Alzheimer’s diseases.
- 16 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (10) , 4799
Open AccessOn the Potential Role of Phytate Against Neurodegeneration: It Protects Against Fe3+-Catalyzed Degradation of Dopamine and Ascorbate and Against Fe3+-Induced Protein Aggregation
Myo-inositol-1,2,3,4,5,6-hexakisphosphate (IP6) is commonly found in plant-derived foods and has important pharmacological properties against many pathologies. One of them appears to be neurodegeneration, which is notably stimulated by dysregulated metal metabolism. Consequently, we explore the role of IP6 in mitigating neurodegenerative events catalyzed by dysregulated free iron. More precisely, we performed spectrophotometric measurements in aqueous solutions to investigate the ability of IP6 to chelate Fe3+ and inhibit its role in catalyzing the oxidative degradation of dopamine and ascorbic acid, two key molecules in neuronal redox systems. Our results demonstrate that IP6 effectively prevents the formation of harmful intermediates, such as neuromelanin and reactive oxygen species, which are linked to neuronal damage. Additionally, we assessed the effect of IP6 on Fe3+-induced protein aggregation, focusing on α-synuclein, which is closely associated with Parkinson’s disease. Our data reveal that IP6 accelerates the conversion of toxic α-synuclein oligomers into less harmful amyloid fibrils, thereby reducing their neurotoxic potential. Our findings highlight the dual function of IP6 as a potent Fe3+ chelator and modulator of protein aggregation pathways, reinforcing its potential as a neuroprotective agent. Consequently, IP6 offers promising therapeutic potential for mitigating the progression of neurodegenerative disorders such as Parkinson’s and Alzheimer’s diseases.
- Open Access
- 29 January 2025
- Published by MDPI AG in Preprints.org
On the Potential Role of Phytate Against Neurodegeneration: It Protects Against Fe3+-Catalyzed Degradation of Dopamine and Ascorbate, and Against Fe3+-Induced Protein Aggregation
Myo-inositol-1,2,3,4,5,6-hexakisphosphate (IP6), commonly found in plant-derived foods, has important pharmacological properties against many pathological processes. One of them could be the neurodegeneration, stimulated by a dysregulated metal metabolism. Consequently, we explore here the role of IP6 in mitigating neurodegenerative processes catalyzed by dysregulated free iron. Using dopamine and ascorbic acid as models of neuronal redox systems, we demonstrate that IP6 effectively chelates Fe³⁺, inhibiting its ability to catalyse the oxidative degradation of DA and AA. Our findings reveal that IP6 prevents the formation of harmful intermediates such as neuromelanin and reactive oxygen species, which are associated with neuronal damage. Furthermore, we examined the effect of IP6 on Fe³⁺-induced protein aggregation, focusing on α-synuclein, a protein directly linked to Parkinson's disease. IP6 altered the aggregation mechanism of αS by accelerating the conversion of toxic oligomers into less harmful amyloid fibrils, thus reducing the potential for neuronal damage. Our results highlight the dual function of IP6 as potent Fe³⁺ chelator and modulator of protein aggregation pathways, thus emphasizing its potential as a neuroprotective agent. Consequently, IP6 offers promising therapeutic features for mitigating the progression of neurodegenerative disorders such as Parkinson’s and Alzheimer’s diseases.
- 29 January 2025
- Published by MDPI AG in Preprints.org
Open AccessOn the Potential Role of Phytate Against Neurodegeneration: It Protects Against Fe3+-Catalyzed Degradation of Dopamine and Ascorbate, and Against Fe3+-Induced Protein Aggregation
Myo-inositol-1,2,3,4,5,6-hexakisphosphate (IP6), commonly found in plant-derived foods, has important pharmacological properties against many pathological processes. One of them could be the neurodegeneration, stimulated by a dysregulated metal metabolism. Consequently, we explore here the role of IP6 in mitigating neurodegenerative processes catalyzed by dysregulated free iron. Using dopamine and ascorbic acid as models of neuronal redox systems, we demonstrate that IP6 effectively chelates Fe³⁺, inhibiting its ability to catalyse the oxidative degradation of DA and AA. Our findings reveal that IP6 prevents the formation of harmful intermediates such as neuromelanin and reactive oxygen species, which are associated with neuronal damage. Furthermore, we examined the effect of IP6 on Fe³⁺-induced protein aggregation, focusing on α-synuclein, a protein directly linked to Parkinson's disease. IP6 altered the aggregation mechanism of αS by accelerating the conversion of toxic oligomers into less harmful amyloid fibrils, thus reducing the potential for neuronal damage. Our results highlight the dual function of IP6 as potent Fe³⁺ chelator and modulator of protein aggregation pathways, thus emphasizing its potential as a neuroprotective agent. Consequently, IP6 offers promising therapeutic features for mitigating the progression of neurodegenerative disorders such as Parkinson’s and Alzheimer’s diseases.
- Open Access
- 28 July 2023
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 247, 112344
Understanding the effect of the membrane-mimetic micelles on the interplay between α-synuclein and Cu(II)/Cu(I) cations
- 28 July 2023
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 247, 112344
Open AccessUnderstanding the effect of the membrane-mimetic micelles on the interplay between α-synuclein and Cu(II)/Cu(I) cations
- Open Access
- 20 June 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (6) , 1310
Tyrosine Nitroxidation Does Not Affect the Ability of α-Synuclein to Bind Anionic Micelles, but It Diminishes Its Ability to Bind and Assemble Synaptic-like Vesicles
Parkinson’s disease (PD) is characterized by dopaminergic neuron degeneration and the accumulation of neuronal inclusions known as Lewy bodies, which are formed by aggregated and post-translationally modified α-synuclein (αS). Oxidative modifications such as the formation of 3-nitrotyrosine (3-NT) or di-tyrosine are found in αS deposits, and they could be promoted by the oxidative stress typical of PD brains. Many studies have tried to elucidate the molecular mechanism correlating nitroxidation, αS aggregation, and PD. However, it is unclear how nitroxidation affects the physiological function of αS. To clarify this matter, we synthetized an αS with its Tyr residues replaced by 3-NT. Its study revealed that Tyr nitroxidation had no effect on either the affinity of αS towards anionic micelles nor the overall structure of the micelle-bound αS, which retained its α-helical folding. Nevertheless, we observed that nitroxidation of Y39 lengthened the disordered stretch bridging the two consecutive α-helices. Conversely, the affinity of αS towards synaptic-like vesicles diminished as a result of Tyr nitroxidation. Additionally, we also proved that nitroxidation precluded αS from performing its physiological function as a catalyst of the clustering and the fusion of synaptic vesicles. Our findings represent a step forward towards the completion of the puzzle that must explain the molecular mechanism behind the link between αS-nitroxidation and PD.
- 20 June 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (6) , 1310
Open AccessTyrosine Nitroxidation Does Not Affect the Ability of α-Synuclein to Bind Anionic Micelles, but It Diminishes Its Ability to Bind and Assemble Synaptic-like Vesicles
Parkinson’s disease (PD) is characterized by dopaminergic neuron degeneration and the accumulation of neuronal inclusions known as Lewy bodies, which are formed by aggregated and post-translationally modified α-synuclein (αS). Oxidative modifications such as the formation of 3-nitrotyrosine (3-NT) or di-tyrosine are found in αS deposits, and they could be promoted by the oxidative stress typical of PD brains. Many studies have tried to elucidate the molecular mechanism correlating nitroxidation, αS aggregation, and PD. However, it is unclear how nitroxidation affects the physiological function of αS. To clarify this matter, we synthetized an αS with its Tyr residues replaced by 3-NT. Its study revealed that Tyr nitroxidation had no effect on either the affinity of αS towards anionic micelles nor the overall structure of the micelle-bound αS, which retained its α-helical folding. Nevertheless, we observed that nitroxidation of Y39 lengthened the disordered stretch bridging the two consecutive α-helices. Conversely, the affinity of αS towards synaptic-like vesicles diminished as a result of Tyr nitroxidation. Additionally, we also proved that nitroxidation precluded αS from performing its physiological function as a catalyst of the clustering and the fusion of synaptic vesicles. Our findings represent a step forward towards the completion of the puzzle that must explain the molecular mechanism behind the link between αS-nitroxidation and PD.
- Open Access
- 20 February 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (2) , 315
Frataxins Emerge as New Players of the Intracellular Antioxidant Machinery
Frataxin is a mitochondrial protein which deficiency causes Friedreich’s ataxia, a cardio-neurodegenerative disease. The lack of frataxin induces the dysregulation of mitochondrial iron homeostasis and oxidative stress, which finally causes the neuronal death. The mechanism through which frataxin regulates the oxidative stress balance is rather complex and poorly understood. While the absence of human (Hfra) and yeast (Yfh1) frataxins turn out cells sensitive to oxidative stress, this does not occur when the frataxin gene is knocked-out in E. coli. To better understand the biological roles of Hfra and Yfh1 as endogenous antioxidants, we have studied their ability to inhibit the formation of reactive oxygen species (ROS) from Cu2+- and Fe3+-catalyzed degradation of ascorbic acid. Both proteins drastically reduce the formation of ROS, and during this process they are not oxidized. In addition, we have also demonstrated that merely the presence of Yfh1 or Hfra is enough to protect a highly oxidation-prone protein such as α-synuclein. This unspecific intervention (without a direct binding) suggests that frataxins could act as a shield to prevent the oxidation of a broad set of intracellular proteins, and reinforces that idea that frataxin can be used to prevent neurological pathologies linked to an enhanced oxidative stress.
- 20 February 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (2) , 315
Open AccessFrataxins Emerge as New Players of the Intracellular Antioxidant Machinery
Frataxin is a mitochondrial protein which deficiency causes Friedreich’s ataxia, a cardio-neurodegenerative disease. The lack of frataxin induces the dysregulation of mitochondrial iron homeostasis and oxidative stress, which finally causes the neuronal death. The mechanism through which frataxin regulates the oxidative stress balance is rather complex and poorly understood. While the absence of human (Hfra) and yeast (Yfh1) frataxins turn out cells sensitive to oxidative stress, this does not occur when the frataxin gene is knocked-out in E. coli. To better understand the biological roles of Hfra and Yfh1 as endogenous antioxidants, we have studied their ability to inhibit the formation of reactive oxygen species (ROS) from Cu2+- and Fe3+-catalyzed degradation of ascorbic acid. Both proteins drastically reduce the formation of ROS, and during this process they are not oxidized. In addition, we have also demonstrated that merely the presence of Yfh1 or Hfra is enough to protect a highly oxidation-prone protein such as α-synuclein. This unspecific intervention (without a direct binding) suggests that frataxins could act as a shield to prevent the oxidation of a broad set of intracellular proteins, and reinforces that idea that frataxin can be used to prevent neurological pathologies linked to an enhanced oxidative stress.
- Open Access
- 10 March 2020
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 11 (12) , 3332-3344
Unravelling the effect of N (ε)-(carboxyethyl)lysine on the conformation, dynamics and aggregation propensity of α-synuclein
We study the effect of an advanced glycation end product ( N (ε)-(carboxyethyl)lysine), found on the Lewy bodies of people suffering from Parkinson’s disease, on the conformational and aggregation features of alpha-synuclein.
- 10 March 2020
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 11 (12) , 3332-3344
Open AccessUnravelling the effect of N (ε)-(carboxyethyl)lysine on the conformation, dynamics and aggregation propensity of α-synuclein
We study the effect of an advanced glycation end product ( N (ε)-(carboxyethyl)lysine), found on the Lewy bodies of people suffering from Parkinson’s disease, on the conformational and aggregation features of alpha-synuclein.
- 1 January 2020
- Published by Elsevier in Inorganica Chimica Acta
- Vol. 499
Understanding metal binding in neuromedin C
- 1 January 2020
- Published by Elsevier in Inorganica Chimica Acta
- Vol. 499
Understanding metal binding in neuromedin C
- Open Access
- 1 September 2019
- Published by MDPI AG in Antioxidants
- Vol. 8 (9) , 344
How Does Pyridoxamine Inhibit the Formation of Advanced Glycation End Products? The Role of Its Primary Antioxidant Activity
Pyridoxamine, one of the natural forms of vitamin B6, is known to be an effective inhibitor of the formation of advanced glycation end products (AGEs), which are closely related to various human diseases. Pyridoxamine forms stable complexes with metal ions that catalyze the oxidative reactions taking place in the advanced stages of the protein glycation cascade. It also reacts with reactive carbonyl compounds generated as byproducts of protein glycation, thereby preventing further protein damage. We applied Density Functional Theory to study the primary antioxidant activity of pyridoxamine towards three oxygen-centered radicals (•OOH, •OOCH3 and •OCH3) to find out whether this activity may also play a crucial role in the context of protein glycation inhibition. Our results show that, at physiological pH, pyridoxamine can trap the •OCH3 radical, in both aqueous and lipidic media, with rate constants in the diffusion limit (>1.0 × 108 M s ). The quickest pathways involve the transfer of the hydrogen atoms from the protonated pyridine nitrogen, the protonated amino group or the phenolic group. Its reactivity towards •OOH and •OOCH3 is smaller, but pyridoxamine can still scavenge them with moderate rate constants in aqueous media. Since reactive oxygen species are also involved in the formation of AGEs, these results highlight that the antioxidant capacity of pyridoxamine is also relevant to explain its inhibitory role on the glycation process.- 1 September 2019
- Published by MDPI AG in Antioxidants
- Vol. 8 (9) , 344
Open AccessHow Does Pyridoxamine Inhibit the Formation of Advanced Glycation End Products? The Role of Its Primary Antioxidant Activity
Pyridoxamine, one of the natural forms of vitamin B6, is known to be an effective inhibitor of the formation of advanced glycation end products (AGEs), which are closely related to various human diseases. Pyridoxamine forms stable complexes with metal ions that catalyze the oxidative reactions taking place in the advanced stages of the protein glycation cascade. It also reacts with reactive carbonyl compounds generated as byproducts of protein glycation, thereby preventing further protein damage. We applied Density Functional Theory to study the primary antioxidant activity of pyridoxamine towards three oxygen-centered radicals (•OOH, •OOCH3 and •OCH3) to find out whether this activity may also play a crucial role in the context of protein glycation inhibition. Our results show that, at physiological pH, pyridoxamine can trap the •OCH3 radical, in both aqueous and lipidic media, with rate constants in the diffusion limit (>1.0 × 108 M s ). The quickest pathways involve the transfer of the hydrogen atoms from the protonated pyridine nitrogen, the protonated amino group or the phenolic group. Its reactivity towards •OOH and •OOCH3 is smaller, but pyridoxamine can still scavenge them with moderate rate constants in aqueous media. Since reactive oxygen species are also involved in the formation of AGEs, these results highlight that the antioxidant capacity of pyridoxamine is also relevant to explain its inhibitory role on the glycation process. - 1 May 2019
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 129, 254-266
Does glycation really distort the peptide α-helicity?
- 1 May 2019
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 129, 254-266
Does glycation really distort the peptide α-helicity?
- 11 April 2019
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 10 (6) , 2919-2930
Nitration and Glycation Diminish the α-Synuclein Role in the Formation and Scavenging of Cu2+-Catalyzed Reactive Oxygen Species
Human α-synuclein is a small monomeric protein (140 residues) essential to maintain the function of the dopaminergic neurons and the neuronal redox balance. However, it holds a dark side since it is able to clump inside the neurons forming insoluble aggregates known as Lewy bodies, which are considered the hallmark of Parkinson’s disease. Sporadic mutations and non-enzymatic post-translational modifications are well-known to stimulate the formation of Lewy bodies. Yet, the effect of non-enzymatic post-translational modifications on the function of α-synuclein has been studied less intense. Therefore, here we study how nitration and glycation mediated by methylglyoxal affect the redox features of α-synuclein. Both diminish the ability of α-synuclein to chelate Cu2+, except when Nε-(carboxyethyl)lysine or Nε-(carboxymethyl)lysine (two advanced glycation end products highly prevalent in vivo) are formed. This results into a lower capacity to prevent the Cu-catalyzed ascorbic acid degradation and to delay the formation of H2O2. However, only methylglyoxal was able to abolish the ability of α-synuclein to inhibit the free radical release. Both nitration and glycation enhanced the α-synuclein availability to be damaged by O2·-, although glycation made α-synuclein less reactive towards HO·. Our data represent the first report describing how non-enzymatic post-translational modifications might affect the redox function of α-synuclein, thus contributing to a better understanding of its pathological implications.
- 11 April 2019
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 10 (6) , 2919-2930
Nitration and Glycation Diminish the α-Synuclein Role in the Formation and Scavenging of Cu2+-Catalyzed Reactive Oxygen Species
Human α-synuclein is a small monomeric protein (140 residues) essential to maintain the function of the dopaminergic neurons and the neuronal redox balance. However, it holds a dark side since it is able to clump inside the neurons forming insoluble aggregates known as Lewy bodies, which are considered the hallmark of Parkinson’s disease. Sporadic mutations and non-enzymatic post-translational modifications are well-known to stimulate the formation of Lewy bodies. Yet, the effect of non-enzymatic post-translational modifications on the function of α-synuclein has been studied less intense. Therefore, here we study how nitration and glycation mediated by methylglyoxal affect the redox features of α-synuclein. Both diminish the ability of α-synuclein to chelate Cu2+, except when Nε-(carboxyethyl)lysine or Nε-(carboxymethyl)lysine (two advanced glycation end products highly prevalent in vivo) are formed. This results into a lower capacity to prevent the Cu-catalyzed ascorbic acid degradation and to delay the formation of H2O2. However, only methylglyoxal was able to abolish the ability of α-synuclein to inhibit the free radical release. Both nitration and glycation enhanced the α-synuclein availability to be damaged by O2·-, although glycation made α-synuclein less reactive towards HO·. Our data represent the first report describing how non-enzymatic post-translational modifications might affect the redox function of α-synuclein, thus contributing to a better understanding of its pathological implications.